Drug intelligence / Profile preview

3Z-20-002

Development stage: Preclinical
Lead developer: 3Z Pharmaceuticals
Modality: Small Molecules

Overview

3Z-20-002 is a preclinical small-molecule adrenergic α1 receptor agonist being developed by 3Z ehf (3Z Pharmaceuticals) for the treatment of attention deficit disorder with hyperactivity (ADHD). It was identified using 3Z’s zebrafish-based behavioral screening platform and is being advanced under a 505(b)(2) regulatory strategy as a repurposed drug candidate, with demonstrated proof of concept in zebrafish models but no reported clinical data yet.[5][9][13]

Targets

ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on 3Z-20-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3Z-20-002.

Explore the full profile